RYTM Similar Chart Price Prediction
The price of RYTM is predicted to go up -6.05%, based on the high correlation periods with G. The similarity of these two price pattern on the periods is 91.43%.
RYTM
G
Down: -6.05%Similarity: 91.43%
RYTM Revenue Forecast
RYTM EPS Forecast
RYTM FAQs
What is bull’s view on RYTM?
What is bear's view on RYTM?
What is RYTM revenue forecast for next quarter？
RYTM Analyst's Forecast
Leland Gershell
Oppenheimer
Buy
2024-12-20
Price Target
$76
Upside
+35.42%
Oppenheimer initiated coverage of Rhythm Pharmaceuticals with an Outperform rating and $76 price target. The firm says the company is "distinguished" by its focus on rare obesity disorders for which commonly-prescribed drugs are poorly suited. As Rhythm builds a business through Imcivree's global commercialization for several genetically-driven diseases, the revenue outlook in hypothalamic obesity, an acquired condition for which Oppenheimer sees a high likelihood of development success, drives enthusiasm ahead of the first half of 2025 Phase 3 results, the analyst tells investors in a research note. The firm believes leadership in MC4 biology should position Rhythm for "enduring prosperity."
Seamus Fernandez
Guggenheim
Strong Buy
2024-10-21
Price Target
$70
Upside
+39.47%
Tazeen Ahmad
B of A Securities
Hold
2024-10-14
Price Target
$48 → $52
Upside
+3.5%
